3-(4-methoxyphenyl)-4-(4-hydroxybenzoyl)-1,2-dihydronaphthalene | 63619-83-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 3-(4-methoxyphenyl)-4-(4-hydroxybenzoyl)-1,2-dihydronaphthalene
• 英文别名: LY 126412；(4-Hydroxyphenyl)<3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl>methanone；4-(4-hydroxybenzoyl)-3-(4-methoxyphenyl)-1,2-dihydronaphthalene；(4-hydroxyphenyl)-[2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]methanone
• CAS: 63619-83-0
• 化学式: C₂₄H₂₀O₃
• 分子量: 356.421
• InChiKey: UNOQWPOQMYOWJF-UHFFFAOYSA-N

物化性质

• 沸点：
  566.6±50.0 °C(Predicted)
• 密度：
  1.232±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-methoxyphenyl)-4-(4-hydroxybenzoyl)-1,2-dihydronaphthalene 以 甲烷磺酸 、 水 为溶剂， 生成 11-(4-hydroxyphenyl)-9-methoxy-11H-benzo[a]fluorene
  参考文献：
  名称：

  Benzo[a]fluorene compounds

  摘要：

  苯环上在11位位置具有氨基烷氧基基团的苯并[a]芴类化合物具有雌激素和抗雌激素活性。

  公开号：

  US05147880A1
• 作为产物：
  描述：

  3-(4-methoxyphenyl)-4-(4-methoxybenzoyl)-1,2-dihydronaphthalene 在 乙硫醇钠 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 以83%的产率得到3-(4-methoxyphenyl)-4-(4-hydroxybenzoyl)-1,2-dihydronaphthalene
  参考文献：
  名称：

  Regioselectivity in the Alkaline Thiolate Deprotection of Aryl Methyl Ethers

  摘要：

  DOI：

  10.1021/jo00108a046

文献信息

• Naphthyl bradykinin receptor antagonists
  申请人：Eli Lilly and Company

  公开号：US05514675A1

  公开（公告）日：1996-05-07

  This invention provides methods of treating a physiological disorder associated with an excess of bradykinins in a mammal which comprises administering to a mammal in need of said treatment a compound selected from a series of substituted dihydronaphthalenes and naphthalenes.

  这项发明提供了治疗与哺乳动物体内布雷金肽过量相关的生理紊乱的方法，包括向需要该治疗的哺乳动物施用从一系列取代二氢萘烯和萘烯中选择的化合物。
• Methods for treating resistant tumors
  申请人：Eli Lilly and Company

  公开号：US06124311A1

  公开（公告）日：2000-09-26

  The present invention provides methods for reversing multidrug resistance in a resistant neoplasm by treating a mammal in need of said treatment with a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene. This invention also provides methods for treating neoplasms in a mammal which comprises administering to a mammal in need of this treatment a substituted indole, benzofuran, benzothiophene, naphthalene, or dihydronaphthalene in combination with an oncolytic agent.

  本发明提供了通过给需要治疗的哺乳动物使用取代吲哚、苯并呋喃、苯并噻吩、萘或二氢萘来逆转耐药新生物的方法。本发明还提供了治疗哺乳动物中的新生物的方法，包括向需要此治疗的哺乳动物施用取代吲哚、苯并呋喃、苯并噻吩、萘或二氢萘与一个溶瘤剂的组合。
• Methods of treating neuropeptide Y-associated conditions
  申请人：ELI LILLY AND COMPANY

  公开号：EP0759441A3

  公开（公告）日：1999-06-30

  This invention describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

  这项发明描述了治疗与神经肽Y过量相关的疾病的方法，包括给予肥胖蛋白的类似物。这项发明进一步描述了治疗与神经肽Y过量相关的疾病的方法，包括给予肥胖蛋白的类似物结合神经肽Y拮抗剂。这项发明证明了肥胖蛋白通过减少下丘脑产生神经肽Y来发挥作用。
• Methods of treating nueropeptide Y-associated conditions
  申请人：Eli Lilly and Company

  公开号：US05972888A1

  公开（公告）日：1999-10-26

  This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein. This invention also describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.

  这项发明描述了治疗与神经肽Y过量相关的疾病的方法，包括给予一种肥胖蛋白。这项发明还描述了治疗与神经肽Y过量相关的疾病的方法，包括给予一种肥胖蛋白和神经肽Y拮抗剂的组合。这项发明证明了肥胖蛋白通过减少下丘脑产生神经肽Y来发挥作用。
• Naphthyl tachykinin receptor antagonists to treat physiological
  申请人：Eli Lilly and Company

  公开号：US05491140A1

  公开（公告）日：1996-02-13

  This invention provides methods of treating a physiological disorder associated with an excess of tachykinins in a mammal which comprises administering to a mammal in need of said treatment a compound selected from a series of substituted dihydronaphthalenes and naphthalenes.

  这项发明提供了治疗与哺乳动物体内过量的缓激肽相关的生理紊乱的方法，包括向需要该治疗的哺乳动物施用从一系列取代二氢萘烯和萘烯中选择的化合物。